In quiet debut, Alzheimer's drug finds questions, skepticism

The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough when regulators approved it more than four months ago, but its rollout has been slowed by questions about its price and how well it works.

Related Keywords

Rhode Island ,United States ,Boston ,Massachusetts ,Dallas ,Texas ,Washington ,Los Angeles ,Stephen Salloway ,Maha Radhakrishnan ,Brendan Kelley ,Salim Syed ,Wendy Van Fossen ,Neurology Center ,Ut Southwestern Medical Center ,Japan Eisai Co ,Drug Administration ,Cleveland Clinic ,Mass General Brigham ,Mizuho Securities United ,Medical Center ,Van Fossen ,Biogen Chief Medical Officer ,Zaldy Tan ,Medicare Advantage ,